Skip to main content
SpringerLink
Log in

An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation

  • ORIGINAL ARTICLE
  • Published:
International Journal of Legal Medicine Aims and scope Submit manuscript

Abstract

An in vitro inhibition study was performed to investigate potential drug–drug interactions on glucuronidation of buprenorphine (BUP) and norbuprenorphine (NBUP), which represents the major elimination pathway of the drug using cDNA-expressed uridine 5′-diphosphate glucuronosyltransferases (UGTs) and human liver microsomes (HLMs). Following identification of major UGT enzymes for BUP and NBUP glucuronidation, substrates were incubated with drugs (amitriptyline, nortriptyline, lamotrigine, oxazepam, and temazepam), which are extensively cleared by glucuronidation as well as are often used during maintenance treatment. To evaluate the inhibitory potential, the half maximal inhibitor concentration (IC50), the inhibition constant (K i), and the inhibitor concentration (K I) that yield half the maximum rate of inactivation and the enzyme inactivation rate constant (k inact) were determined, if appropriate. Amitriptyline and temazepam are inhibitors of NBUP glucuronidation (UGT1A3, HLMs), whereas BUP glucuronidation was affected by amitriptyline (HLMs), oxazepam, and temazepam (UGT2B7). Additionally, BUP inhibits NBUP glucuronidation (UGT1A1, 1A3, HLMs) and vice versa (UGT1A3). A decrease in the metabolic clearance of NBUP may increase the risk of adverse effects such as respiratory depression. Further investigations are needed to evaluate whether inhibition of BUP and NBUP glucuronidation contributes to adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lufty K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395–402

    Article  Google Scholar 

  2. Elkader A, Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661–680

    Article  CAS  PubMed  Google Scholar 

  3. Huang W, Moody DE, McCance-Katz EF (2006) The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography–electrospray ionization–tandem mass spectrometry. Ther Drug Monit 28:245–251

    Article  CAS  PubMed  Google Scholar 

  4. Drogen- und Suchtbericht (2008). http://www.bmg.bund.de

  5. Kintz P (2002) A new series of 13 buprenorphine-related deaths. Clin Biochem 35:513–516

    Article  CAS  PubMed  Google Scholar 

  6. Bomsien S, Aderjan R, Mattern R, Skopp G (2006) Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur J Clin Pharmacol 62:639–643

    Article  CAS  PubMed  Google Scholar 

  7. Megarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ (2006) Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 25:79–85

    Article  CAS  PubMed  Google Scholar 

  8. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12:577–581

    CAS  PubMed  Google Scholar 

  9. Chang Y, Moody DE (2009) Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Letters 3:101–107

    Article  CAS  Google Scholar 

  10. Kintz P (2001) Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 121:65–69

    Article  CAS  PubMed  Google Scholar 

  11. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170–171

    CAS  PubMed  Google Scholar 

  12. Kitz R, Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245–3249

    CAS  PubMed  Google Scholar 

  13. Worm K, Steentoft A, Kringsholm B (1993) Methadone and drug addicts. Int J Legal Med 106:119–123

    Article  CAS  PubMed  Google Scholar 

  14. Kaa E, Teige B (1993) Drug-related deaths during the 1980s. A comparative study of drug addict deaths examined at the institutes of forensic medicine in Aarhus, Denmark, and Oslo, Sweden. Int J Legal Med 106:5–9

    Article  CAS  PubMed  Google Scholar 

  15. Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G (2000) Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 45:226–228

    CAS  PubMed  Google Scholar 

  16. Boyd J, Randell T, Luurila H, Kuisma M (2003) Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 47:1031–1033

    Article  CAS  PubMed  Google Scholar 

  17. Skopp G, Bomsien S, Zimmer G (2008) Buprenorphin und Benzodiazepine - ein potentiell tödlicher Cocktail? J Addiction Res Pract 54:188–189

    Google Scholar 

  18. Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833

    Article  CAS  PubMed  Google Scholar 

  19. Miners JO, McKinnon RA, Mackenzie PI (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181–182:453–456

    Article  PubMed  Google Scholar 

  20. Argikar UA, Iwuchukwu OF, Nagar S (2008) Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Expert Opin Drug Metab Toxicol 4:879–894

    Article  CAS  PubMed  Google Scholar 

  21. Miners JO, Knights KM, Houston JB, Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531–1539

    Article  CAS  PubMed  Google Scholar 

  22. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423–459

    Article  CAS  PubMed  Google Scholar 

  23. Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol Ther 106:97–132

    Article  CAS  PubMed  Google Scholar 

  24. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacol (Berl) 128:398–407

    Article  Google Scholar 

  25. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro–in vivo extrapolation. J Pharmacol Exp Ther 321:137–147

    Article  CAS  PubMed  Google Scholar 

  26. Murphy CM, Huestis MA (2005) Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma. J Mass Spectrom 40:70–74

    Article  CAS  PubMed  Google Scholar 

  27. Hara Y, Nakajima M, Miyamoto K, Yokoi T (2007) Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab Pharmacokinet 22:103–112

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We acknowledge Dr. R. Garcia Boy for thoroughly reviewing the manuscript. This work was supported by a grant from the Deutsche Forschungsgemeinschaft (Sk 48/3-1).

Author information

Authors and Affiliations

  1. Institute of Legal Medicine and Traffic Medicine, University Hospital, Voss-Str. 2, 69115, Heidelberg, Germany

    Stephanie Oechsler & Gisela Skopp

Authors
  1. Stephanie Oechsler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gisela Skopp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie Oechsler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oechsler, S., Skopp, G. An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation. Int J Legal Med 124, 187–194 (2010). https://doi.org/10.1007/s00414-010-0418-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00414-010-0418-8

Keywords

Search

Navigation